PureTech Health plc (PTCHF)
- Previous Close
2.7600 - Open
2.7000 - Bid --
- Ask --
- Day's Range
2.7000 - 2.7000 - 52 Week Range
1.6900 - 3.1000 - Volume
50,000 - Avg. Volume
27,516 - Market Cap (intraday)
753.313M - Beta (5Y Monthly) 0.93
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2300 - Earnings Date Apr 25, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.50
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
www.puretechhealth.comRecent News: PTCHF
Performance Overview: PTCHF
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PTCHF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PTCHF
Valuation Measures
Market Cap
755.10M
Enterprise Value
453.30M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
994.69
Price/Book (mrq)
1.57
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-13.09%
Return on Equity (ttm)
-13.25%
Revenue (ttm)
3.33M
Net Income Avi to Common (ttm)
-65.7M
Diluted EPS (ttm)
-0.2300
Balance Sheet and Cash Flow
Total Cash (mrq)
327.14M
Total Debt/Equity (mrq)
29.57%
Levered Free Cash Flow (ttm)
-114.8M
Research Analysis: PTCHF
Company Insights: PTCHF
PTCHF does not have Company Insights